Work

The combination of PI3Ki and MEKi as a promising treatment option for melanoma patients with NRAS-mutated tumors

Year: 2025

Type: article

Abstract: Background: Introduction: In recent years, new therapeutic approaches such as immune checkpoint inhibitors and targeted therapies have improved the survival rate of melanoma patients. However, response rates are limited and resistance to immuno-oncology therapies is a major challenge. The PI3K/AKT signaling pathway is deregulated in 70% of melanomas and contributes to the development of resistance, making PI3K a promising target for inhibitor treatment. In particular, the combination of PI3K and MEK inhibitors could be an effective option, as far as MEKi is the only targeted treatment option for patients with NRAS mutated tumors available.

Source: EJC Skin Cancer

DOI: 10.1016/j.ejcskn.2025.100476

Authors: H. Niessner, L. Fröhlich, T. Wagner, C. Garbe, L. Flatz, T. Sinnberg

Institutions: University of Tübingen, Natural and Medical Sciences Institute, Stiftung Charité, Charité - Universitätsmedizin Berlin

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,340